ShangBay Capital

Evident Vascular specializes in advanced intravascular ultrasound (IVUS) technology, enhanced by artificial intelligence. Their platform automatically identifies and segments key vascular structures in real-time, aiding clinicians in decision-making and improving patient care during peripheral vascular image-guided therapies.

Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

Inquis Medical is a company focused on developing innovative thrombectomy technology aimed at enhancing the management of venous thromboembolic diseases. The company’s medical devices are designed to address unmet clinical needs and improve the standard of care in this field. By offering an efficient single-pass thrombectomy solution with minimal blood loss, Inquis Medical aims to provide healthcare professionals with advanced tools that can significantly impact patient outcomes and long-term health management.

Venova Medical is a company focused on developing innovative vascular access systems for patients undergoing renal replacement therapy, particularly those requiring hemodialysis. Founded in 2018 and headquartered in Los Gatos, California, Venova Medical aims to improve the quality of vascular access by addressing both patient-level and systemic barriers associated with access creation. The company's solutions are designed to facilitate quickly functioning access with reduced need for medical interventions, ultimately enhancing patient outcomes and lowering costs associated with hemodialysis. Through its advancements, Venova Medical seeks to simplify the process of obtaining vascular access for patients in need of critical renal therapies.

Avation Medical, Inc. is a company focused on developing a non-invasive closed-loop neuromodulation system aimed at treating overactive bladder in a home setting. Incorporated in 2016 and based in Columbus, Ohio, Avation Medical is at the forefront of innovation in wearable nerve stimulation systems. The company emphasizes empowering patients to manage their therapies, facilitating a more personalized approach to care. By leveraging advanced technologies, Avation Medical seeks to transform the neuromodulation market, enhancing the quality of care for individuals with chronic conditions through patient-centric solutions.

Laplace Interventional is a medical device company specializing in the development of transcatheter tricuspid valve technology. This innovative technology aims to enhance life expectancy and improve the quality of life for patients suffering from tricuspid regurgitation. The company's prosthetic valve is delivered through a minimally invasive procedure, eliminating the need for open-heart surgery. By offering a less invasive treatment option, Laplace Interventional enables healthcare providers to mitigate future complications for patients, thereby contributing to a better overall health outcome.

Luminopia is a company focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. By creating engaging digital therapeutics, Luminopia aims to provide effective solutions that are rigorously evaluated for FDA approval. Their flagship product, Luminopia One, leverages binocular vision techniques to address amblyopia, enabling healthcare professionals to offer new treatment options for affected patients. Partnering with Boston Children’s Hospital, Luminopia is at the forefront of pioneering advanced therapeutic approaches that enhance patient care in the field of pediatric vision health.

Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, founded in 2017. The company specializes in developing a transformative neuromodulation technology platform aimed at treating chronic pain and other disorders related to neuronal activity. By employing biotechnology, Presidio Medical seeks to create bioelectronic medicine solutions that establish a new class of therapeutic devices, ultimately providing patients with effective remedies for various neural-related conditions.

Solenic Medical, Inc. is a medical device company that focuses on developing a non-invasive treatment for infected metallic implants. Founded in 2019 and based in College Station, Texas, the company employs alternating magnetic fields generated from external coils to eliminate biofilm on the surfaces of these implants. This innovative technology aims to address significant complications that arise from surgeries, including knee and hip replacements, as well as in trauma-related implants such as plates and rods. Solenic Medical's approach offers the potential to replace the costly and risk-laden two-step revision surgical procedure currently used to manage chronic infections in medical implants.

Noah Medical is a manufacturer of medical robotic devices specialized in the diagnosis and treatment of patients across various medical conditions. The company's innovative devices facilitate early diagnoses and treatments within advanced clinical environments, empowering hospitals to address health issues promptly. This capability not only enhances patient outcomes but also contributes to reduced scarring, thereby improving the overall quality of care.

Flare Therapeutics is a biotechnology company dedicated to developing small molecule medicines through a novel approach to understanding transcription factors. By identifying 'switch sites,' which are druggable regions crucial for regulating transcription factors, Flare aims to target mutations that lead to various diseases. The company has rapidly advanced its drug discovery efforts, creating an emerging pipeline of programs initially focused on precision oncology. Additionally, Flare's innovative platform holds promise for addressing conditions in neurology, rare genetic disorders, immunology, and inflammation, ultimately enabling medical professionals to transform treatment strategies for patients.

Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

Telesair is a medical device company focused on creating innovative respiratory care solutions aimed at enhancing the quality of life for individuals with lung diseases. By leveraging real clinical data, advanced engineering design, software, and Internet of Things (IoT) technology, Telesair develops respiratory care equipment that is both safer and more efficient for use in clinical and home settings. Their solutions facilitate the transition of patients from hospital environments to home care, thereby improving overall standards of care within the healthcare system.

Luminopia is a company focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. By creating engaging digital therapeutics, Luminopia aims to provide effective solutions that are rigorously evaluated for FDA approval. Their flagship product, Luminopia One, leverages binocular vision techniques to address amblyopia, enabling healthcare professionals to offer new treatment options for affected patients. Partnering with Boston Children’s Hospital, Luminopia is at the forefront of pioneering advanced therapeutic approaches that enhance patient care in the field of pediatric vision health.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

Huma.AI, Inc. is a technology company based in Palo Alto, California, founded in 2016. It specializes in developing a knowledge automation platform aimed at improving efficiency within the healthcare and pharmaceutical industries. The platform addresses the challenges posed by complex and disparate data systems by connecting various data silos through natural human language. By extracting insights from unstructured data, such as documents and free text, Huma.AI enables users—including companies, scientists, and clinicians—to easily access information and make informed decisions quickly. This innovative approach not only streamlines data access but also allows users to interact with data using everyday language, thereby enhancing the decision-making process in healthcare.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

Laplace Interventional is a medical device company specializing in the development of transcatheter tricuspid valve technology. This innovative technology aims to enhance life expectancy and improve the quality of life for patients suffering from tricuspid regurgitation. The company's prosthetic valve is delivered through a minimally invasive procedure, eliminating the need for open-heart surgery. By offering a less invasive treatment option, Laplace Interventional enables healthcare providers to mitigate future complications for patients, thereby contributing to a better overall health outcome.

Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Neuro42 specializes in the development and commercialization of advanced MRI and robotics technology aimed at improving the diagnosis and treatment of neurological conditions. The company designs portable magnetic resonance imaging machines that facilitate triaging, screening, diagnosing, and intervening in various brain disorders, including traumatic injuries, epilepsy, and tumors. By providing point-of-care solutions, Neuro42 enhances patient access to critical imaging and enables direct robotic interventions outside conventional MRI suites, particularly benefiting individuals who have experienced strokes. This innovative approach aims to streamline neurological care and improve patient outcomes through advanced imaging and intervention technologies.

Emboline, Inc. is a medical device company focused on developing innovative cardiovascular embolic protection devices for a variety of transcatheter and surgical cardiac procedures. Founded in 2011 and based in Santa Cruz, California, the company has created technologies such as Emboline Complete Accessible Protection, which provides embolic protection for the arterial bed, and the Emboliner, an embolic protection catheter designed to safeguard cerebral arteries. These products are particularly beneficial during percutaneous heart valve repair and replacement procedures, as well as in interventional cardiology and electrophysiology markets. Emboline's devices are engineered to conform to diverse patient anatomies and include features that allow for the capture and removal of emboli, thereby enhancing the safety of critical medical procedures.

EpimAb Biotherapeutics, based in Shanghai, China, is a biopharmaceutical research and development company focused on creating innovative bispecific antibody therapeutics, particularly for immuno-oncology. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, EpimAb develops bispecific antibodies that combine the properties of two different monoclonal antibodies into a single molecule. This unique approach aims to address the limitations of traditional antibody therapies, offering potential solutions for various life-threatening diseases, including cancer. The company recognizes the challenges associated with developing bi-specific antibodies, such as maintaining their drug-like properties and ensuring adequate production. By advancing its pipeline of bispecific therapeutics, EpimAb seeks to meet the growing demand for effective treatment options in the pharmaceutical industry.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

Aqua Medical, Inc. is a medical technology company that specializes in developing vapor-based, endoscopic ablation systems aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. Founded in 2016 by Virender K. Sharma, the company is headquartered in Santa Ana, California. Its innovative ablation technology utilizes high-temperature water vapor generated by a radiofrequency generator, which is delivered endoscopically through proprietary catheters to various parts of the gastrointestinal tract. This platform enables medical practitioners to perform effective, non-surgical treatments for conditions such as pancreatic cysts and esophageal issues, offering a convenient and efficient alternative to traditional surgical methods.

OrthoFX, LLC is a Fremont, California-based company that specializes in online clear aligner technology for orthodontic treatment. Established in 2018, OrthoFX offers a comprehensive clear aligner solution tailored for orthodontists and general dentists, enhancing the patient experience through innovative technologies. Its platform includes features such as virtual treatment coordinators, wear-time tracking sensors, and AI-driven remote treatment monitoring. Additionally, OrthoFX utilizes proprietary polymers and provides insurance concierge services, all aimed at streamlining the orthodontic process and reducing the need for treatment reboots. Through these advancements, OrthoFX seeks to improve both the efficiency of dental practices and the overall experience for patients seeking teeth straightening solutions.

Zeto Inc. is a medical technology company based in Santa Clara, California, focusing on revolutionizing the field of electroencephalography (EEG). Founded in 2014, Zeto has developed an innovative, FDA-cleared EEG system that features a wireless, easy-to-wear headset equipped with dry electrodes. This system addresses longstanding challenges in traditional EEG procedures, which often require extensive setup time and trained technicians. Zeto's solution allows for a streamlined process, reducing setup time from over 30 minutes to just 5 minutes while enhancing the patient experience. Complementing the headset, Zeto's cloud-based platform facilitates instant data upload, live viewing, and analytical tools, enabling remote interpretation by neurologists. The company has garnered recognition for its contributions to the field, receiving multiple awards and funding, including support from the Epilepsy Foundation and accolades from various medical innovation showcases.

Zap Surgical Systems, based in San Carlos, California, specializes in developing advanced medical technologies. Founded in 2014, the company's flagship product is ZAP-X, a gyroscopic radiosurgery platform designed for precise, non-invasive treatment of brain tumors and head & neck conditions. Unlike traditional systems, ZAP-X's self-shielded design eliminates the need for radiation vaults, enabling its use in various healthcare settings previously unfeasible or cost-prohibitive.

Meditrina, Inc. is a medical device company based in San Jose, California, established in 2016. The company specializes in developing innovative tissue removal solutions specifically designed for intrauterine pathology. Its flagship product, the Aveta System, serves healthcare professionals by providing an all-in-one solution for hysteroscopic diagnostic and therapeutic procedures, such as the removal of polyps and fibroids. The Aveta System is notable for its compact design, which allows for seamless integration into various clinical settings, including offices and operating rooms. It features advanced capabilities such as wide-angle HD hysteroscopy, improved fluid management for better pressure control, and a small insertion diameter coupled with a large working channel, all of which contribute to optimized tissue resection and enhanced procedural efficiency.

Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

Corinth MedTech, Inc. is a medical technology company based in Cupertino, California, specializing in the manufacture of innovative disposable bipolar transurethral and transcervical resectoscopes. Established in 2011, the company has developed systems designed for endoscopically controlled tissue removal, primarily targeting male patients with benign prostatic hyperplasia (BPH) and female patients facing issues such as abnormal uterine bleeding, fibroids, or polyps. Corinth MedTech's proprietary bipolar resecting devices enable medical professionals to perform effective and precise procedures, facilitating the treatment of enlarged prostates and, potentially, bladder tumors. The company aims to improve patient outcomes through its advanced technology in urology and gynecology.

Apostle, Inc. is a biotechnology company based in Menlo Park, California, specializing in AI-enabled nanoDiagnostics technology for early cancer detection. Founded in 2017, the company focuses on the research, development, licensing, and sales of innovative bioinformatics-enabled nanotechnologies for diagnosing and treating diseases, particularly cancer. Apostle develops advanced liquid biopsy technologies that utilize circulating free DNA as a biomarker, offering solutions such as Apostle MiniMax for efficient cfDNA capture, Apostle MagTouch for nucleic acid isolation automation, and Apostle MiniEnrich for high-resolution DNA size enrichment. In response to the COVID-19 pandemic, the company also introduced a viral RNA isolation system. Apostle operates a CLIA Certified clinical laboratory, Apostle Diagnostics, which is committed to providing accurate and timely clinical testing services, having served over 30,000 individuals to date.

Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative ophthalmic solutions. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses, which address the needs of the intraocular lens replacement market. Atia Vision's technology features an accommodating base that responds to the ciliary muscles of the eye, simulating natural accommodation and allowing for subsequent refractive corrections. This approach restores the full range of functional vision for cataract patients, effectively improving patient outcomes by eliminating the need for glasses. The company's commitment to advancing eye care is reflected in its goal to enhance the quality of life for individuals through innovative medical devices that expedite market entry while minimizing risk.

Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company specializes in the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights offers an integrated platform that includes proprietary consumables such as OptoSelect chips and reagent kits, along with automation systems and application software. Utilizing innovative micro-droplet technology, the company transforms biological processes, enabling researchers to study cell interactions more effectively. This platform supports various applications, including biotherapeutic discovery and development, cellular therapy manufacturing, and synthetic biology, addressing the growing demands in these fields.

NeuroVasc Technologies, Inc. is a medical device company based in Laguna Hills, California, specializing in the development of catheter-based technologies for the treatment of neurovascular diseases, particularly acute ischemic strokes. Founded in 2015, the company has created a thrombectomy system known as Versi, which includes a flow protector and a retriever that can be delivered through a microcatheter. This innovative system allows for the regulation of blood flow during clot retrieval without the use of a balloon guide catheter. NeuroVasc Technologies aims to provide a comprehensive portfolio of tools to enhance treatment options for patients suffering from strokes, thereby supporting physicians in effectively addressing these critical medical conditions.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

Emboline, Inc. is a medical device company focused on developing innovative cardiovascular embolic protection devices for a variety of transcatheter and surgical cardiac procedures. Founded in 2011 and based in Santa Cruz, California, the company has created technologies such as Emboline Complete Accessible Protection, which provides embolic protection for the arterial bed, and the Emboliner, an embolic protection catheter designed to safeguard cerebral arteries. These products are particularly beneficial during percutaneous heart valve repair and replacement procedures, as well as in interventional cardiology and electrophysiology markets. Emboline's devices are engineered to conform to diverse patient anatomies and include features that allow for the capture and removal of emboli, thereby enhancing the safety of critical medical procedures.

Zenflow, Inc. is a medical device company focused on developing innovative solutions for urinary obstruction caused by benign prostatic hyperplasia (BPH) in men. Founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists, Zenflow aims to address the significant unmet clinical need for effective and less invasive treatments. The company markets a unique spring device designed to relieve permanent BPH symptoms by gently propping open the urethra, thereby restoring its normal function while preserving the natural anatomy. This approach prioritizes patient experience, offering a treatment option that is less invasive and less painful compared to traditional methods. Zenflow is headquartered in San Francisco, California.

Ceribell, Inc. is a medical technology company based in Mountain View, California, that specializes in the design and manufacture of devices for acquiring and interpreting electroencephalography (EEG) data. Founded in 2014, Ceribell focuses on making EEG technology more accessible, efficient, and cost-effective, particularly in acute care settings. The company's flagship product, the Ceribell EEG System, includes a portable EEG headband and a compact recorder that provide clinical-quality EEG results without the need for a trained EEG technologist. This system can be set up by healthcare providers in just six minutes, facilitating quicker clinical decision-making. An innovative feature of the Ceribell System is its Brain Stethoscope function, which translates brainwave patterns into sound to aid in the detection of seizures, including non-convulsive seizures. This capability enables earlier diagnosis and targeted treatment, potentially reducing mortality, length of hospital stays, and the risk of complications for patients with serious neurological conditions.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.